高频业务便捷办：支持"异地备案""信息查询"等高频医保业务线上办理，有效分流窗口压力，打破时间 与空间限制，非工作时段也能保障群众顺畅办事，让医保服务更高效省心。 场景延伸多元化：深度融合医院服务场景，未来将拓展"诊间结算""异地结算报错协同""住院查房辅 助""就诊指南查询""专家信息介绍"等多元功能，从医保服务延伸至全流程就医场景，打造一站式智能 服务生态。 作为具备多模态交互能力的人工智能体，"小金灵"能主动精准感知用户意图、理解复杂语义。未来将深 度融合医院"服务知识库"，延伸"诊间结算""异地结算报错协同""住院查房辅助""门诊就诊指南""住院服 务指南""内线电话查询""专家信息介绍"等多元化功能，将服务从医保领域全面拓展至全流程就医场 景，为患者提供一站式、人性化的智能服务，让就医之路更顺畅。 数字化转型浪潮下，人工智能已成为优化医疗服务、破解就医痛点的核心引擎， 近日，江苏省人民医 院（南京医科大学第一附属医院、江苏省妇幼保健院）携手南京医保引入智能服务载体"小金灵"正式入 驻医院。 该院院长刘云表示，"小金灵"入驻是医院智慧医疗服务建设的关键突破，也是AI技术赋能医保服务的重 要实践。医院始 ...

每经编辑｜金冥羽 1月6日，三大指数集体收涨，沪指高开高走，再创十年新高。A股全天成交额达2.83万亿元，较上一个交易日放量2650亿元。全市场超4100只个股上涨， 其中有143只个股涨停，连续两日超百股涨停。从板块来看，商业航天概念持续爆发，脑机接口概念延续强势，截至收盘，沪指涨1.5%，深成指涨1.4%， 创业板指涨0.75%。 盘后，多只商业航天、脑机接口概念牛股齐发公告提示风险。 中国卫星：目前股价已处于历史最高点，公司股价已脱离基本面 中国卫星公告，公司股票自2025年12月3日以来收盘价格累计上涨幅度为156.07%，同期申万军工行业涨幅23.92%，上证A指涨幅5.31%，公司股票短期涨 幅明显高于同期行业及上证指数涨幅，但公司基本面未发生重大变化，存在市场情绪过热、非理性炒作风险，公司股票击鼓传花效应明显，交易风险极 大，存在股价短期快速回落风险。 目前股价已处于历史最高点，公司股价已脱离基本面，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 6天4板中国卫通：股价已严重脱离基本面 公司股票"击鼓传花"效应十分明显 中国卫通发布股票交易风险提示性公告称，公司股票短期涨幅高于同期行业 ...

Group 1 - Xinfeng Pharmaceutical is facing criminal charges for unit bribery, which may negatively impact its profits [2] - Aerospace Electronics has seen a stock price increase of 123.23% since November 27, 2025, significantly outpacing the industry and market, indicating potential irrational market behavior [3] - Chipone Technology has completed the acquisition of Zhudian Semiconductor, gaining a 40% stake and control over the company [4] Group 2 - Chaoying Electronics has increased its investment in AI high-end printed circuit board expansion from 1.468 billion to 3.315 billion yuan, with a production capacity target of 166,500 square meters annually [5] - Yihuilong's Brain Machine Star Chain is developing non-invasive brain-machine interface products, but they are still in early stages and not yet registered [6] - Aerospace Changfeng has confirmed it is not engaged in brain-machine interface or commercial aerospace businesses, despite being categorized as such [7] Group 3 - Guosheng Technology's stock will be suspended for trading on January 7, 2026, due to significant price fluctuations, with a cumulative increase of 370.20% since October 31, 2025 [9] - Xiangyu Medical focuses on non-invasive brain-machine interface technology, with no large-scale sales achieved yet, but aims to cover over 1,000 top-tier hospitals by 2026 [10] - Jiamai Packaging's stock has risen by 230.48% from December 17, 2025, leading to a trading suspension for review [11] Group 4 - Zhongtai Co. expects a net profit of 420 million to 480 million yuan for 2025, recovering from a loss of 77.96 million yuan in the previous year [19] - Lier Chemical anticipates a net profit increase of 113.62% to 132.19% for 2025, driven by rising product demand [20] - Pengding Holdings reported a 30.74% increase in consolidated revenue for December 2025, totaling 424.355 million yuan [21] Group 5 - Times New Materials signed a sales contract for wind turbine blades worth approximately 3.32 billion yuan [31] - Jinggong Steel Structure won a bid for a project worth 824 million yuan, representing 4.46% of its latest audited revenue [32] - Robotech's subsidiary ficonTEC signed a significant contract worth approximately 7.7 million euros for automated optical switch packaging [33]

近年来，中国医疗机构床位规模保持增势，每千人床位数已突破7张，远超欧美发达国家。与之相对 应的是公立医院住院率居高不下，上级医院虹吸病人而医疗"强基"缺少需求侧支撑。在此背景下，今 年国家卫健委将以"强基、稳二、控三"为原则，进一步调控三级医院规模和发展速度。 1月5日至6日，全国卫生健康工作会议在北京召开，会议在部署2026年工作时提出，今年全国卫生 健康系统要"倾力推进深化医改政策落实"，推进以公益性为导向的公立医院改革，与此同时，精准实 施医疗卫生强基和康复护理扩容提升工程。 "按照'强基、稳二、控三'原则优化医疗机构功能定位和结构，持续推进医疗卫生强基工程，稳定二级 医院运行并拓展康复护理功能，调控三级医院规模、发展速度，优化结构，全面提升医疗卫生服务公 益性、可及性和能力水平。"会议称。 根据国家卫健委去年12月发布的《2024年我国卫生健康事业发展统计公报》，2024年，公立医院床 位扩张态势有所减缓，但全国床位规模仍整体继续增加，每千人口医疗卫生机构床位数由2023年 2026.01. 06 本文字数：944，阅读时长大约1分钟 作者 | 第一财经 吴斯旻 （注：我们会对线索进行核实。您的隐私将 ...

Core Viewpoint - TPG is nearing a deal to acquire Optum UK's business from UnitedHealth, with the transaction valued between £1.2 billion and £1.4 billion, and an announcement may come in the next few weeks, although the deal is not finalized and could still fall through [1] Group 1 - The acquisition price for Optum UK is reported to be between £1.2 billion and £1.4 billion [1] - TPG may seek to merge Optum UK with Nextech, a US-based electronic medical records software provider [1] - The deal is expected to be announced in the coming weeks, but it remains subject to finalization [1]

今日焦点 20CM两连板三博脑科：目前不涉及脑机接口产品的研发、生产及销售 三博脑科公告称，公司股票于2026年1月5日、1月6日连续两个交易日内收盘价格涨幅偏离值累计超过 30%，属于股票交易异常波动情形。公司是以神经专科为特色的医疗服务集团，下属院区主要为患者提 供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销售，神经调 控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响，敬请注意投资风险。 2连板翔宇医疗：截至2025年末脑机接口相关产品尚未实现规模化销售 翔宇医疗发布异动公告，近期资本市场对人脑工程、脑机接口等概念关注度较高，相关板块股价涨幅较 大。公司目前主要聚焦非侵入式脑机接口技术，覆盖作业疗法、运动疗法、认知言语、吞咽等康复全场 景布局，与当前国际上的侵入式脑机接口技术路线存在差异。公司在脑机接口方面的投入，目前在技 术、产品、渠道市场等方面形成一定的布局，但招投标和销售等具有滞后性，截至2025年末，相关产品 尚未实现规模化销售，营收占比较小。 6天4板中国卫通：目前股价已处于历史最高点，已严重脱离基本面存在短期大幅下跌的风险 中国卫通发布股票交易风 ...

【导读】多只牛股公告 兄弟姐妹们啊，今晚多只商业航天、脑机接口概念的牛股齐发公告，不是停牌核查就是提示风险！ 6天4板北斗星通：商业航天仅为公司产品和服务的应用场景之一 中国卫星（600118）公告，公司股票自2025年12月3日以来收盘价格累计上涨幅度为156.07%，同期申 万军工行业涨幅23.92%，上证A指涨幅5.31%，公司股票短期涨幅明显高于同期行业及上证指数涨幅， 但公司基本面未发生重大变化，存在市场情绪过热、非理性炒作风险，公司股票击鼓传花效应明显，交 易风险极大，存在股价短期快速回落风险。 北斗星通（002151）公告称，公司股票交易价格连续3个交易日收盘价格涨幅偏离值累计超过20%，属 于股票交易异常波动情形。公司留意到近期市场对于商业航天概念股的关注度颇高，公司主营业务为卫 星导航芯片、模组、天线、数据服务，下游应用场景包括测量测绘、智能驾驶、智慧农业、割草机器 人、无人机等，商业航天仅为公司产品和服务的应用场景之一，请投资者注意风险。 航天环宇：预计2025年公司商业航天相关收入占比不足15% 航天环宇公告，公司股票于2025年12月31日、2026年1月5日、1月6日连续三个交易日内 ...

Group 1 - The core viewpoint of the article highlights that International Medical (000516) has established a strong competitive edge and influence in the medical field through significant capital investments in the past [1] - Since the full opening of Xi'an International Medical Center Hospital, the company has experienced substantial growth in overall business scale, with a steady development trend and increasing brand influence and patient recognition [1] - From 2025 onwards, the company has faced a decrease in operating revenue year-on-year due to ongoing adjustments in industry policies, particularly the deepening of medical insurance payment reforms [1] Group 2 - The company will adhere to its strategic development goals, focusing on stable operations, enhancing medical quality and service experience, and building competitive advantages through differentiated strategies [1] - The company aims to actively adapt to industry changes and achieve continuous optimization of operational efficiency and improvement in business performance [1]

| 最高: 54.97 | 今年:4 | | --- | --- | | 最低:49.98 | 昨收:49 | | 量比: 0.70 | 换手:10 | | 委比:100.00% | 振幅:9. | | 每股收益:-0.49 | 股息(TTI | | 每股净资产:9.50 | 股息率(T | | 52周最高: 54.97 | 52周最低 | 【导读】多只牛股公告 中国基金报记者 泰勒 兄弟姐妹们啊，今晚多只商业航天、脑机接口概念的牛股齐发公告，不是停牌核查就是提示风险！ 6天4板北斗星通： 商业航天仅为公司产品和服务的应用场景之一 北斗星通公告称，公司股票交易价格连续3个交易日收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形。公司留意 到近期市场对于商业航天概念股的关注度颇高，公司主营业务为卫星导航芯片、模组、天线、数据服务，下游应用场景包括测量 测绘、智能驾驶、智慧农业、割草机器人、无人机等，商业航天仅为公司产品和服务的应用场景之一，请投资者注意风险。 | 成交量: 74.80万手 | | --- | | 成交额:39.95亿 | | 市盈率(TTM)： | | 市净率:5.79 | | 总市值: ...

Core Viewpoint - Baihua Pharmaceutical (600721) announced the termination of the planned change in control due to a lack of consensus with the counterparties, and the company's stock will resume trading on January 7, 2026 [1][2]. Group 1: Control Change Announcement - The controlling shareholders and actual controllers, Mi Naqi, Mi Enhua, and Yang Xiaoling, decided to terminate the control change due to disagreements on significant matters [1]. - The company had previously announced a potential share transfer that could lead to a change in control, prompting a temporary suspension of trading to ensure fair information disclosure and protect investor interests [1]. Group 2: Business Operations and Financial Performance - The company stated that the termination of the control change will not have a significant adverse impact on its operational performance and financial status [2]. - Baihua Pharmaceutical's main business includes early drug discovery, CMC development, clinical trials, registration applications, and various pharmaceutical services, providing comprehensive outsourcing and technology transfer services [2]. - For the first three quarters of 2025, the company reported revenue of 299 million yuan, a year-on-year increase of 2.74%, and a net profit of 32.67 million yuan, reflecting a year-on-year growth of 36.41% [3].